Factor This Power Engineering
Live Events
DTECH® Events
POWERGENâ¢
Calendar
Webinars
Podcasts
Contribute Content
Solar
Community
Residential
Utility Scale
Wind Power
Offshore
Turbines & Equipment
Power Grid
Distribution
Grid Modernization
Microgrids
Outage Management
Smart Grids
Transmission
Hydropower
Dams & Civil Structures
Small Hydropower
Technology & Equipment
Tidal & Wave Energy
Energy Storage
Battery
Long Duration
Pumped Storage
Business
Finance
Policy & Regulation
Project Development
Tariffs
Electric Vehicles
EV Charging
Vehicle to Grid
Subscribe
Solar
Community
Residential
Utility Scale
Wind Power
Offshore
Turbines & Equipment
Power Grid
Distribution
Grid Modernization
Microgrids
Outage Management
Transmission
Smart Grids
Hydropower
Dams & Civil Structures
Small Hydro
Technology & Equipment
Tidal & Wave Energy
Energy Storage
Battery
Long Duration
Pumped Storage
Business
Finance
Policy & Regulation
Electric Vehicles
EV Charging
Vehicle to Grid
Factor This: Power Engineering
Live Events
DISTRIBUTECH®
Podcasts
Webinars
Calendar
Contribute Content
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Hydroworld Market Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Trevi Therapeutics, Inc. - Common Stock
(NQ:
TRVI
)
11.41
+0.45 (+4.15%)
Streaming Delayed Price
Updated: 1:53 PM EST, Feb 3, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Trevi Therapeutics, Inc. - Common Stock
< Previous
1
2
3
4
5
Next >
MarketBeat’s Top 5 Rated Small-Cap Stocks
↗
December 22, 2025
Via
MarketBeat
This Biotech Fund Just Dumped $14.8 Million in MBX Biosciences — Right Before Key 2026 Milestones
↗
December 03, 2025
One fast-rising biotech is gearing up for pivotal trials just as a major specialist fund walks away—here’s what long-term investors should take from that divergence.
Via
The Motley Fool
Topics
Initial Public Offering
Regulatory Compliance
Biotech Fund Reveals $15 Million MoonLake Exit After Stock’s 90% Crash
↗
November 28, 2025
A brutal 90% single-day crash and a shareholder’s full exit raise the stakes for MoonLake’s upcoming FDA meeting.
Via
The Motley Fool
Topics
Lawsuit
Regulatory Compliance
Biotech Fund Reveals $15 Million MoonLake Exit After Stock’s 90% Crash
↗
November 27, 2025
A brutal 90% single-day crash and a shareholder’s full exit raise the stakes for MoonLake’s upcoming FDA meeting.
Via
The Motley Fool
Topics
Lawsuit
Regulatory Compliance
Earnings Scheduled For November 13, 2025
↗
November 13, 2025
Via
Benzinga
Earnings Scheduled For August 7, 2025
↗
August 07, 2025
Via
Benzinga
Earnings Scheduled For May 8, 2025
↗
May 08, 2025
Via
Benzinga
This Biotech Fund Just Dumped $14.8 Million in MBX Biosciences — Right Before Key 2026 Milestones
↗
November 27, 2025
One fast-rising biotech is gearing up for pivotal trials just as a major specialist fund walks away—here’s what long-term investors should take from that divergence.
Via
The Motley Fool
Topics
Initial Public Offering
Regulatory Compliance
Biotech Fund Dumps $12.3 Million in Crinetics Stock as Shares Remain 19% Lower on the Year
↗
November 27, 2025
Here’s what a complete fund exit reveals about sentiment toward one of biotech’s endocrine drug developers.
Via
The Motley Fool
Topics
Regulatory Compliance
Trevi Therapeutics Inc (NASDAQ:TRVI) Reports Q3 2025 Results, Narrows Loss and Outlines Phase 3 Plans
↗
November 13, 2025
Trevi Therapeutics reported a narrower-than-expected Q3 2025 loss. The biopharma firm is preparing its Phase 3 program for Haduvio and has cash into 2028.
Via
Chartmill
Earnings Preview For Trevi Therapeutics
↗
May 07, 2025
Via
Benzinga
A Peek at Trevi Therapeutics's Future Earnings
↗
November 12, 2025
Via
Benzinga
12 Health Care Stocks Moving In Friday's After-Market Session
↗
October 03, 2025
Via
Benzinga
10 Health Care Stocks Whale Activity In Today's Session
↗
September 09, 2025
Via
Benzinga
This Adient Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday
↗
August 21, 2025
Via
Benzinga
Dow Gains Over 100 Points; US Job Openings Increase In April
↗
June 03, 2025
Via
Benzinga
Topics
Stocks
Trevi Therapeutics Showcases Drug That Cuts Cough Frequency In Lung Disease Patients
↗
June 02, 2025
Trevi's Haduvio met its primary endpoint in a Phase 2b trial for IPF-related chronic cough, with statistically significant results at multiple doses.
Via
Benzinga
Earnings Scheduled For March 18, 2025
↗
March 18, 2025
Via
Benzinga
Unusual volume stocks are being observed in Tuesday's session.
↗
March 11, 2025
In today's session, these stocks are experiencing unusual volume.
Via
Chartmill
Let's uncover which stocks are experiencing notable gaps during today's session.
↗
March 10, 2025
The session on Monday is off to an intriguing start with several stocks showing significant price gaps. Let's examine the gap up and gap down stocks in today's session.
Via
Chartmill
Redfin, Mineralys Therapeutics, Trevi Therapeutics And Other Big Stocks Moving Higher On Monday
↗
March 10, 2025
Via
Benzinga
Trevi Therapeutics Reveals Positive Data From Mid-Stage Study For Chronic Cough Candidate, Stock Jumps
↗
March 10, 2025
Trevi's Haduvio met the primary endpoint in a Phase 2a trial, showing a significant reduction in cough frequency with no serious adverse events reported.
Via
Benzinga
Top movers in Monday's pre-market session
↗
March 10, 2025
The US market is yet to commence its session on Monday, but let's get a preview of the pre-market session and explore the top gainers and losers driving the early market movements.
Via
Chartmill
Why Checkpoint Therapeutics Shares Are Trading Higher By Around 66%; Here Are 20 Stocks Moving Premarket
↗
March 10, 2025
Via
Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session
↗
December 12, 2024
Via
Benzinga
Dow Tumbles 200 Points; Liquidity Services Shares Spike Higher
↗
December 12, 2024
Via
Benzinga
Topics
Stocks
Gold Falls Sharply; Adobe Shares Dip After Weak Revenue Outlook
↗
December 12, 2024
Via
Benzinga
Nasdaq Down 50 Points; US Initial Jobless Claims Rise
↗
December 12, 2024
Via
Benzinga
Why Is Cough-Focused Trevi Therapeutics Stock Skyrocketing On Thursday?
↗
December 12, 2024
Trevi Therapeutics' CORAL trial progresses unchanged after a positive SSRE review, with topline results for chronic cough in IPF expected by mid-2025.
Via
Benzinga
TRVI Stock Earnings: Trevi Therapeutics Misses EPS for Q2 2024
↗
August 08, 2024
TRVI stock results show that Trevi Therapeutics missed analyst estimates for earnings per share the second quarter of 2024.
Via
InvestorPlace
< Previous
1
2
3
4
5
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
